MiNK Therapeutics (INKT) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $9.41, -5.33% vs the prior close of $9.94.
- Volume 13.62K shares, 0.9x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
INKT slides 5.3% to $9.41, a 6-month low. Closed at $9.41, -5.33% vs the prior close of $9.94. Day range $9.40–$10.05, opened at $9.87.
INKT daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — INKT slides 5.3% to $9.41, a 6-month low
- Closed at $9.41, -5.33% vs the prior close of $9.94. Day range $9.40–$10.05, opened at $9.87.
- Volume was 13.62K shares, 0.9x its 50-day average of 14.80K.
- Price is -18.4% vs its 50-day average ($11.53) and -17.2% vs its 200-day average ($11.37).
- 52-week range $8.48–$16.93; today's close sits at 11% of that range, 44.4% below the 52-week high.
Oct 15, 2026 — INKT slides 4.0% to $9.94, a 6-month low
- Closed at $9.94, -3.96% vs the prior close of $10.35. Day range $9.93–$10.35, opened at $10.35.
- Volume was 10.10K shares, 0.7x its 50-day average of 14.90K.
- Price is -14.0% vs its 50-day average ($11.56) and -12.6% vs its 200-day average ($11.38).
- 52-week range $8.48–$16.93; today's close sits at 17% of that range, 41.3% below the 52-week high.
Oct 14, 2026 — INKT rises 1.2% to $10.35
- Closed at $10.35, +1.17% vs the prior close of $10.23. Day range $10.09–$10.35, opened at $10.17.
- Volume was 6.00K shares, 0.4x its 50-day average of 14.99K — lighter than usual.
- Price is -10.7% vs its 50-day average ($11.59) and -9.1% vs its 200-day average ($11.39).
- 52-week range $8.48–$16.93; today's close sits at 22% of that range, 38.9% below the 52-week high.
Oct 13, 2026 — INKT dips 2.8% to $10.23, a 3-month low, 8 down days in a row
- Closed at $10.23, -2.85% vs the prior close of $10.53. Day range $10.12–$10.65, opened at $10.44.
- Volume was 7.20K shares, 0.5x its 50-day average of 14.96K — lighter than usual.
- Price is -11.9% vs its 50-day average ($11.61) and -10.2% vs its 200-day average ($11.40).
- 52-week range $8.48–$16.93; today's close sits at 21% of that range, 39.6% below the 52-week high.
- That makes 8 straight losses.
Oct 12, 2026 — INKT dips 1.8% to $10.53, a 1-month low, 7 down days in a row
- Closed at $10.53, -1.77% vs the prior close of $10.72. Day range $10.36–$11.24, opened at $10.90.
- Volume was 18.80K shares, 1.3x its 50-day average of 14.66K.
- Price is -9.3% vs its 50-day average ($11.62) and -7.7% vs its 200-day average ($11.40).
- 52-week range $8.48–$16.93; today's close sits at 24% of that range, 37.8% below the 52-week high.
- That makes 7 straight losses.
Oct 9, 2026 — INKT dips 2.5% to $10.72, a 1-month low, 6 down days in a row
- Closed at $10.72, -2.55% vs the prior close of $11.00. Day range $10.68–$10.96, opened at $10.96.
- Volume was 17.00K shares, 1.2x its 50-day average of 14.44K.
- Price is -7.7% vs its 50-day average ($11.62) and -6.1% vs its 200-day average ($11.41).
- 52-week range $8.48–$16.93; today's close sits at 27% of that range, 36.7% below the 52-week high.
- That makes 6 straight losses.
Oct 8, 2026 — INKT slides 3.7% to $11.00, a 1-month low, 5 down days in a row
- Closed at $11.00, -3.68% vs the prior close of $11.42. Day range $10.96–$11.56, opened at $11.56.
- Volume was 10.60K shares, 0.7x its 50-day average of 14.37K.
- Price is -5.3% vs its 50-day average ($11.61) and -3.6% vs its 200-day average ($11.42).
- 52-week range $8.48–$16.93; today's close sits at 30% of that range, 35.0% below the 52-week high.
- That makes 5 straight losses.
Oct 7, 2026 — INKT dips 2.4% to $11.42, 4 down days in a row
- Closed at $11.42, -2.39% vs the prior close of $11.70. Day range $11.32–$11.63, opened at $11.63.
- Volume was 13.80K shares, 1.0x its 50-day average of 14.23K.
- Price is -1.6% vs its 50-day average ($11.60) and +0.0% vs its 200-day average ($11.42).
- 52-week range $8.48–$16.93; today's close sits at 35% of that range, 32.5% below the 52-week high.
- That makes 4 straight losses.
Oct 6, 2026 — INKT slides 4.1% to $11.70 on 2.4x normal volume
- Closed at $11.70, -4.10% vs the prior close of $12.20. Day range $11.63–$12.20, opened at $12.11.
- Volume was 33.00K shares, 2.4x its 50-day average of 13.77K — unusually heavy trading.
- Price is +1.0% vs its 50-day average ($11.58) and +2.5% vs its 200-day average ($11.42).
- 52-week range $8.48–$16.93; today's close sits at 38% of that range, 30.9% below the 52-week high.
- That makes 3 straight losses.
Oct 5, 2026 — INKT dips 1.9% to $12.20 on 2.1x normal volume
- Closed at $12.20, -1.93% vs the prior close of $12.44. Day range $12.10–$12.84, opened at $12.51.
- Volume was 28.60K shares, 2.1x its 50-day average of 13.60K — unusually heavy trading.
- Price is +5.5% vs its 50-day average ($11.56) and +6.8% vs its 200-day average ($11.42).
- 52-week range $8.48–$16.93; today's close sits at 44% of that range, 27.9% below the 52-week high.
Oct 2, 2026 — INKT dips 2.3% to $12.44 on 3.8x normal volume
- Closed at $12.44, -2.28% vs the prior close of $12.73. Day range $12.10–$12.72, opened at $12.72.
- Volume was 48.90K shares, 3.8x its 50-day average of 12.74K — unusually heavy trading.
- Price is +7.8% vs its 50-day average ($11.54) and +8.9% vs its 200-day average ($11.42).
- 52-week range $8.48–$16.93; today's close sits at 47% of that range, 26.5% below the 52-week high.
INKT latest news & SEC filings
Every SEC filing by or about INKT in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 14, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Buell Jennifer converted options/RSUs into 23,191 shares on Oct 11, 2026; now holds 81,133
- Buell Jennifer sold 6,938 shares at $10.56 (≈$73.27K) on Oct 12, 2026; now holds 74,195
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 13, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 13, 2026 · Form S-8 — Employee share plan registration
Registration of shares for employee stock plans (S-8)
Aug 13, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$3.13M (prior year -$4.24M) (loss narrowed vs Jun 30, 2025)
- Diluted EPS: -$0.62 (prior year -$1.06) (loss narrowed vs Jun 30, 2025)
Aug 13, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jun 23, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.07 — Reported shareholder vote results.
Things to know before you trade INKT
- Last results release: Aug 13, 2026 (8-K Item 2.02). Previous ones: May 15, 2026, Mar 31, 2026, Dec 8, 2025. Based on that rhythm, the next report is likely around Nov 12, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.19% (largest 5.3%).
- Liquidity: about 19.11K shares (≈$179.83K) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $9.41 vs a range of $8.48–$16.93 (11% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: 1:10 on Jan 28, 2025
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Barbara Ryan sold 1,000 shares on Jun 4, 2026.
- Latest filings: 10-Q Aug 13, 2026; 8-K Aug 13, 2026; 8-K Jun 23, 2026.
- Share count: 5.10M shares outstanding (Aug 11, 2026), +12.8% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
INKT market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 9.87 | 10.05 | 9.40 | 9.41 | 13.62K |
| Oct 15, 2026 | 10.35 | 10.35 | 9.93 | 9.94 | 10.10K |
| Oct 14, 2026 | 10.17 | 10.35 | 10.09 | 10.35 | 6.00K |
| Oct 13, 2026 | 10.44 | 10.65 | 10.12 | 10.23 | 7.20K |
| Oct 12, 2026 | 10.90 | 11.24 | 10.36 | 10.53 | 18.80K |
| Oct 9, 2026 | 10.96 | 10.96 | 10.68 | 10.72 | 17.00K |
| Oct 8, 2026 | 11.56 | 11.56 | 10.96 | 11.00 | 10.60K |
| Oct 7, 2026 | 11.63 | 11.63 | 11.32 | 11.42 | 13.80K |
| Oct 6, 2026 | 12.11 | 12.20 | 11.63 | 11.70 | 33.00K |
| Oct 5, 2026 | 12.51 | 12.84 | 12.10 | 12.20 | 28.60K |
| Oct 2, 2026 | 12.72 | 12.72 | 12.10 | 12.44 | 48.90K |
| Oct 1, 2026 | 12.71 | 12.96 | 12.49 | 12.73 | 26.70K |
| Sep 30, 2026 | 12.62 | 12.98 | 12.19 | 12.55 | 61.10K |
| Sep 29, 2026 | 12.18 | 12.59 | 12.09 | 12.26 | 20.20K |
| Sep 28, 2026 | 11.82 | 12.44 | 11.72 | 12.11 | 13.70K |
| Sep 25, 2026 | 12.00 | 12.46 | 11.70 | 12.18 | 11.50K |
| Sep 24, 2026 | 12.36 | 12.42 | 11.75 | 12.30 | 10.00K |
| Sep 23, 2026 | 12.50 | 12.50 | 11.68 | 12.35 | 14.80K |
| Sep 22, 2026 | 12.14 | 12.38 | 11.50 | 12.11 | 8.60K |
| Sep 21, 2026 | 11.84 | 12.69 | 11.57 | 12.25 | 8.00K |
About MiNK Therapeutics
MiNK Therapeutics (INKT) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in NEW YORK, NY. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1840229.
INKT board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Peter Behner | Director | Sep 2, 2026 |
| Brian Corvese | Director | Sep 2, 2026 |
| John Bradley Holcomb | Director | Sep 2, 2026 |
| Robert Peter Kadlec | Director | Dec 3, 2025 |
| Barbara Ryan | Director | Sep 2, 2026 |
| Ulf Wiinberg | Director | Sep 2, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Jennifer Buell | Chief Executive Officer | Jan 14, 2026 |
| Austin Charette | Principal Accounting Officer | Mar 23, 2026 |
| Melissa Orilall | Principal Financial Officer | Apr 9, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 4, 2026 | Barbara Ryan | Sale | 1,000 | $12.80 |
| Jun 4, 2026 | Barbara Ryan | Sale | 500 | $12.68 |
| Jun 4, 2026 | Barbara Ryan | Sale | 1,000 | $12.80 |
| Jun 4, 2026 | Barbara Ryan | Sale | 500 | $12.68 |
| Jun 4, 2026 | Barbara Ryan | Sale | 1,000 | $12.80 |
| Jun 4, 2026 | Barbara Ryan | Sale | 500 | $12.68 |
| Jun 4, 2026 | Barbara Ryan | Sale | 1,000 | $12.80 |
| Jun 4, 2026 | Barbara Ryan | Sale | 500 | $12.68 |
| Mar 10, 2026 | Barbara Ryan | Sale | 500 | $15.30 |
| Mar 10, 2026 | Barbara Ryan | Sale | 500 | $15.57 |
| Mar 10, 2026 | Barbara Ryan | Sale | 300 | $15.28 |
| Mar 10, 2026 | Barbara Ryan | Sale | 500 | $15.30 |
| Mar 10, 2026 | Barbara Ryan | Sale | 500 | $15.57 |
| Mar 10, 2026 | Barbara Ryan | Sale | 300 | $15.28 |
| Mar 10, 2026 | Barbara Ryan | Sale | 500 | $15.30 |
INKT financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-12.49M | -2.93 | $-5.93M |
| Dec 31, 2024 | — | $-10.78M | -2.86 | $-9.56M |
| Dec 31, 2023 | — | $-22.46M | -6.54 | $-15.76M |
| Dec 31, 2022 | — | $-27.99M | -0.83 | $-18.87M |
| Dec 31, 2021 | — | $-30.21M | -1.16 | $-12.83M |
Latest balance sheet: total assets $9.62M, total liabilities $—, cash $8.81M (as of Jun 30, 2026).
INKT earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 13, 2026 | 8-K Item 2.02 (results) | $11.00 |
| May 15, 2026 | 8-K Item 2.02 (results) | $10.72 |
| Mar 31, 2026 | 8-K Item 2.02 (results) | $10.53 |
| Dec 8, 2025 | 8-K Item 2.02 (results) | $12.01 |
| Aug 14, 2025 | 8-K Item 2.02 (results) | $15.32 |
| May 15, 2025 | 8-K Item 2.02 (results) | $7.18 |
| Mar 18, 2025 | 8-K Item 2.02 (results) | $8.24 |
| Nov 14, 2024 | 8-K Item 2.02 (results) | $7.50 |
| Aug 13, 2024 | 8-K Item 2.02 (results) | — |
| May 14, 2024 | 8-K Item 2.02 (results) | — |
| Mar 21, 2024 | 8-K Item 2.02 (results) | — |
| Nov 9, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Revolution Medicines (RVMD)Argenx Se (ARGX)Kodiak Sciences (KOD)Greenland Mines (GRML)Halozyme Therapeutics (HALO)Biogen (BIIB)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on INKT
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.